Nephros Stock Quote Today


USD 1.72  0.06  3.37%   

Market Performance
0 of 100
Odds Of Distress
Over 97
Nephros is trading at 1.72 as of the 11th of August 2022. This is a -3.37 percent decrease since the beginning of the trading day. The stock's open price was 1.78. Nephros has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Nephros are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of August 2020 and ending today, the 11th of August 2022. Click here to learn more.
Fiscal Year End
Business Domain
Consumer Durables & Apparel
IPO Date
21st of September 2004
Consumer Discretionary
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. The company has 10.32 M outstanding shares of which 32.73 K shares are now shorted by private and institutional investors with about 1.3 trading days to cover. More on Nephros
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Nephros Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Nephros' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Nephros or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Nephros generated a negative expected return over the last 90 days
Nephros may become a speculative penny stock
Nephros has high historical volatility and very poor performance
Nephros has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 9.86 M. Net Loss for the year was (5.54 M) with profit before overhead, payroll, taxes, and interest of 5.74 M.
Nephros currently holds about 5.42 M in cash with (3.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52.
Latest headline from Nephros to Release Earnings on Wednesday - Defense World
CEODaron Evans
Average Analyst Recommendation
Analysts covering Nephros report their recommendations after researching Nephros' financial statements, talking to executives and customers, or listening in on Nephros' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Nephros. The Nephros consensus assessment is calculated by taking the average forecast from all of the analysts covering Nephros.
Strong Buy3 Opinions
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Nephros' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Nephros (NEPH) is traded on NASDAQ Exchange in USA and employs 34 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 19.04 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nephros's market, we take the total number of its shares issued and multiply it by Nephros's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Nephros conducts business under Healthcare sector and is part of Medical Instruments & Supplies industry. The entity has 10.32 M outstanding shares of which 32.73 K shares are now shorted by private and institutional investors with about 1.3 trading days to cover. Nephros currently holds about 5.42 M in cash with (3.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52.
Check Nephros Probability Of Bankruptcy
The market capitalization of Nephros is $19.04 Million. 30% of Nephros outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Allocation (%)

Check Nephros Ownership Details

Nephros Stock Price Odds Analysis

What are Nephros' target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Nephros jumping above the current price in 90 days from now is about 46.02%. The Nephros probability density function shows the probability of Nephros stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Nephros has a beta of -0.0436. This indicates as returns on benchmark increase, returns on holding Nephros are expected to decrease at a much lower rate. During the bear market, however, Nephros is likely to outperform the market. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Nephros is significantly underperforming DOW.
  Odds Below 1.72HorizonTargetOdds Above 1.72
53.85%90 days
Based on a normal probability distribution, the odds of Nephros to move above the current price in 90 days from now is about 46.02 (This Nephros probability density function shows the probability of Nephros Stock to fall within a particular range of prices over 90 days) .

Nephros Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Nephros market risk premium is the additional return an investor will receive from holding Nephros long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Nephros. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Nephros' alpha and beta are two of the key measurements used to evaluate Nephros' performance over the market, the standard measures of volatility play an important role as well.

Nephros Stock Against Markets

Picking the right benchmark for Nephros stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Nephros stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Nephros is critical whether you are bullish or bearish towards Nephros at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nephros without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Focused Opportunities Now


Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Nephros Corporate Directors

Nephros corporate directors refer to members of a Nephros board of directors. The board of directors generally takes responsibility for the Nephros' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Nephros' board members must vote for the resolution. The Nephros board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

Invested in Nephros?

You need to understand the risk of investing before taking a position in Nephros. The danger of trading Nephros is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Nephros is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Nephros. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Nephros is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Stocks Correlation. Note that the Nephros information on this page should be used as a complementary analysis to other Nephros' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Nephros Stock analysis

When running Nephros price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
18.4 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine Nephros value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.